Concept

Perrigo

Summary
Perrigo Company plc is an American Irish–registered manufacturer of private label over-the-counter pharmaceuticals, and while 70% of Perrigo's net sales are from the U.S. healthcare system, Perrigo is legally headquartered in Ireland for tax purposes, which accounts for 0.60% of net sales. In 2013, Perrigo completed the sixth-largest US corporate tax inversion in history when it reregistered its tax status to Ireland to avoid U.S. corporate taxes. Perrigo maintains its corporate headquarters in Grand Rapids, Michigan, within Michigan State University's Grand Rapids Innovation Park. Perrigo engages in the acquisition (for repricing), manufacture, and sale of consumer healthcare products, generic prescription drugs, and active pharmaceutical ingredients (APIs), primarily in the United States, from its base in Ireland. On 21 December 2018, Perrigo suffered its biggest one-day share price fall in its history after the Irish Revenue Commissioners issued a tax claim against Perrigo that equated to half of its market value. Corporation tax in the Republic of Ireland#Corporate tax inversions L. Perrigo Company was founded in 1887 in Allegan, Michigan, by Luther and Charles Perrigo, who ran a general store. In 1991 Perrigo had an initial public offering on NASDAQ. In March 2005 the firm acquired Agis Industries Limited (TASE:AGIS), an Israel-based generic pharmaceuticals company in an 850milliontransaction.Agiswasfoundedin1983byMoriArkinwhodevelopedhisfatherssmalldrugimportbusinessintoamultinationalgenericpharmaceuticalcompany.Asaresultoftheacquisition,Arkinowned9InJuly2013,PerrigoannouncedthatitwouldexecuteacorporatetaxinversiontoIrelandinordertoavoidU.S.corporatetaxes,viaan850 million transaction. Agis was founded in 1983 by Mori Arkin who developed his father's small drug import business into a multinational generic pharmaceutical company. As a result of the acquisition, Arkin owned 9% of Perrigo, and was appointed as Vice Chairman of the company. In July 2013, Perrigo announced that it would execute a corporate tax inversion to Ireland in order to avoid U.S. corporate taxes, via an 8.6 billion acquisition of Irish-based Elan Corporation. , Perrigo is the sixth-largest U.S. tax inversion in history. Over 70% of Perrigo's sales, and an even greater percentage of Perrigo profits, are from the U.S. healthcare system.
About this result
This page is automatically generated and may contain information that is not correct, complete, up-to-date, or relevant to your search query. The same applies to every other page on this website. Please make sure to verify the information with EPFL's official sources.